Level	Gene	Alterations	Cancer Types	Drugs (for therapeutic implications only)
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Imatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Asciminib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Bosutinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Dasatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Imatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Nilotinib
1	ABL1	T315I	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Asciminib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Ponatinib
1	ALK	Fusions	Anaplastic Large-Cell Lymphoma ALK Positive	Crizotinib
1	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Crizotinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Alectinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Brigatinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Ceritinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ALK	Oncogenic Mutations	Non-Small Cell Lung Cancer	Lorlatinib
1	ATM	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BARD1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRAF	V600	Erdheim-Chester Disease	Vemurafenib
1	BRAF	V600	Melanoma	Vemurafenib + Atezolizumab + Cobimetinib
1	BRAF	V600E	All Solid Tumors (excluding Colorectal Cancer)	Dabrafenib + Trametinib
1	BRAF	V600E	Anaplastic Thyroid Cancer	Dabrafenib + Trametinib
1	BRAF	V600E	Biliary Tract Cancer, NOS	Dabrafenib + Trametinib
1	BRAF	V600E	Colorectal Cancer	Encorafenib + Cetuximab
1	BRAF	V600E	Melanoma	Dabrafenib
1	BRAF	V600E	Melanoma	Vemurafenib
1	BRAF	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib
1	BRAF	V600E, V600K	Melanoma	Dabrafenib + Trametinib
1	BRAF	V600E, V600K	Melanoma	Encorafenib + Binimetinib
1	BRAF	V600E, V600K	Melanoma	Trametinib
1	BRAF	V600E, V600K	Melanoma	Vemurafenib + Cobimetinib
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Niraparib
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib, Olaparib + Bevacizumab
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Rucaparib
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Niraparib
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib, Olaparib + Bevacizumab
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Rucaparib
1	BRIP1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CDK12	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CHEK1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CHEK2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Dacomitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Erlotinib, Erlotinib + Ramucirumab
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Gefitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Osimertinib
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Amivantamab
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Mobocertinib
1	EGFR	G719	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	L861Q	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	S768I	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	T790M	Non-Small Cell Lung Cancer	Osimertinib
1	ERBB2	Amplification	Breast Cancer	Ado-Trastuzumab Emtansine
1	ERBB2	Amplification	Breast Cancer	Lapatinib + Capecitabine, Lapatinib + Letrozole
1	ERBB2	Amplification	Breast Cancer	Margetuximab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Neratinib, Neratinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab Deruxtecan
1	ERBB2	Amplification	Breast Cancer	Trastuzumab, Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Pembrolizumab + Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab Deruxtecan
1	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab Deruxtecan
1	EZH2	A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S	Follicular Lymphoma	Tazemetostat
1	FANCL	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	FGFR1	Fusions	Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2	Pemigatinib
1	FGFR2	Fusions	Bladder Cancer	Erdafitinib
1	FGFR2	Fusions	Cholangiocarcinoma	Futibatinib
1	FGFR2	Fusions	Cholangiocarcinoma	Infigratinib
1	FGFR2	Fusions	Cholangiocarcinoma	Pemigatinib
1	FGFR3	Fusions	Bladder Cancer	Erdafitinib
1	FGFR3	G370C, R248C, S249C, Y373C	Bladder Cancer	Erdafitinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Gilteritinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Midostaurin + High Dose Chemotherapy
1	IDH1	R132	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Acute Myeloid Leukemia	Ivosidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Acute Myeloid Leukemia	Olutasidenib
1	IDH2	R140G, R140L, R140Q, R140W, R172G, R172K, R172M, R172S, R172W	Acute Myeloid Leukemia	Enasidenib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	D816	Mastocytosis	Avapritinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Sunitinib
1	KRAS	G12C	Non-Small Cell Lung Cancer	Adagrasib
1	KRAS	G12C	Non-Small Cell Lung Cancer	Sotorasib
1	KRAS	Wildtype	Colorectal Cancer	Cetuximab, Cetuximab + Chemotherapy
1	KRAS	Wildtype	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Capmatinib
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Tepotinib
1	NF1	Oncogenic Mutations	Neurofibroma	Selumetinib
1	NRAS	Wildtype	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy
1	NTRK1	Fusions	All Solid Tumors	Entrectinib
1	NTRK1	Fusions	All Solid Tumors	Larotrectinib
1	NTRK2	Fusions	All Solid Tumors	Entrectinib
1	NTRK2	Fusions	All Solid Tumors	Larotrectinib
1	NTRK3	Fusions	All Solid Tumors	Entrectinib
1	NTRK3	Fusions	All Solid Tumors	Larotrectinib
1	Other Biomarkers	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Ipilimumab + Nivolumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Nivolumab
1	Other Biomarkers	Tumor Mutational Burden-High	All Solid Tumors	Pembrolizumab
1	PALB2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	PDGFB	COL1A1-PDGFB Fusion	Dermatofibrosarcoma Protuberans	Imatinib
1	PDGFRA	Exon 18 in-frame deletions, Exon 18 in-frame insertions, Exon 18 missense mutations	Gastrointestinal Stromal Tumor	Avapritinib
1	PDGFRA	FIP1L1-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	Imatinib
1	PDGFRA	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	PDGFRB	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R	Breast Cancer	Alpelisib + Fulvestrant
1	RAD51B	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD51C	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD51D	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD54L	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RET	Fusions	All Solid Tumors (excluding Thyroid Cancer, Non-Small Cell Lung Cancer)	Selpercatinib
1	RET	Fusions	Non-Small Cell Lung Cancer	Pralsetinib
1	RET	Fusions	Non-Small Cell Lung Cancer	Selpercatinib
1	RET	Fusions	Thyroid Cancer	Pralsetinib
1	RET	Fusions	Thyroid Cancer	Selpercatinib
1	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Pralsetinib
1	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Selpercatinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Entrectinib
1	SMARCB1	Deletion	Epithelioid Sarcoma	Tazemetostat
1	TSC1	Oncogenic Mutations	Encapsulated Glioma	Everolimus
1	TSC2	Oncogenic Mutations	Encapsulated Glioma	Everolimus
R1	ABL1	E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, G250E, T315A, V299L, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Imatinib
R1	ABL1	E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, G250E, T315A, V299L, Y253H	Chronic Myelogenous Leukemia	Imatinib
R1	ABL1	E255K, E255V, F359C, F359I, F359V, G250E, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
R1	ABL1	E255K, E255V, F359C, F359I, F359V, G250E, Y253H	Chronic Myelogenous Leukemia	Nilotinib
R1	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
R1	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	Chronic Myelogenous Leukemia	Dasatinib
R1	ABL1	F317L, G250E, V299L	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
R1	ABL1	F317L, G250E, V299L	Chronic Myelogenous Leukemia	Bosutinib
R1	ABL1	T315I	B-Lymphoblastic Leukemia/Lymphoma	Imatinib, Dasatinib, Nilotinib, Bosutinib
R1	ABL1	T315I	Chronic Myelogenous Leukemia	Imatinib, Dasatinib, Nilotinib, Bosutinib
R1	BTK	C481S	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R1	EGFR	Exon 20 in-frame insertions (excluding A763_Y764insFQEA)	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Afatinib
R1	EGFR	T790M	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Afatinib
R1	KRAS	Oncogenic Mutations	Colorectal Cancer	Cetuximab, Panitumumab
R1	NRAS	Oncogenic Mutations	Colorectal Cancer	Cetuximab, Panitumumab
R1	NTRK1	G595R	All Solid Tumors	Larotrectinib
R1	NTRK3	F617L	All Solid Tumors	Larotrectinib
R1	NTRK3	G623R	All Solid Tumors	Larotrectinib
R1	NTRK3	G696A	All Solid Tumors	Larotrectinib
R1	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib
2	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
2	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
2	ABL1	E255K, E255V, F317C, F317I, F317V, F359C, F359I, F359V, T315A, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
2	ABL1	E255K, E255V, F317C, F317I, F317V, F359C, F359I, F359V, T315A, Y253H	Chronic Myelogenous Leukemia	Bosutinib
2	ABL1	E255K, E255V, F359C, F359I, F359V, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
2	ABL1	E255K, E255V, F359C, F359I, F359V, Y253H	Chronic Myelogenous Leukemia	Dasatinib
2	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
2	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	Chronic Myelogenous Leukemia	Nilotinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Brigatinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Ceritinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Lorlatinib
2	ARAF	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	ARAF	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	ARAF	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	BRAF	Fusions	Pilocytic Astrocytoma	Selumetinib
2	BRAF	Oncogenic Mutations (excluding V600)	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	BRAF	Oncogenic Mutations (excluding V600)	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	BRAF	Oncogenic Mutations (excluding V600)	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	BRAF	V600	Langerhans Cell Histiocytosis	Vemurafenib, Dabrafenib
2	BRAF	V600 (excluding V600E and V600K)	Melanoma	Dabrafenib + Trametinib
2	BRAF	V600 (excluding V600E and V600K)	Melanoma	Encorafenib + Binimetinib
2	BRAF	V600 (excluding V600E and V600K)	Melanoma	Vemurafenib + Cobimetinib
2	BRAF	V600E	Colorectal Cancer	Encorafenib + Panitumumab
2	BRAF	V600E	Diffuse Glioma	Vemurafenib + Cobimetinib
2	BRAF	V600E	Encapsulated Glioma	Vemurafenib + Cobimetinib
2	BRAF	V600E	Hairy Cell Leukemia	Vemurafenib
2	BRAF	V600E	Pilocytic Astrocytoma	Selumetinib
2	BRAF	V600E	Pleomorphic Xanthoastrocytoma, Pilocytic Astrocytoma, Ganglioglioma	Vemurafenib + Cobimetinib
2	BRCA1	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Rucaparib
2	BRCA2	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Rucaparib
2	BRCA2	Oncogenic Mutations	Uterine Sarcoma	Olaparib, Rucaparib, Niraparib
2	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Erlotinib
2	EGFR	G719	Non-Small Cell Lung Cancer	Osimertinib
2	EGFR	L861Q	Non-Small Cell Lung Cancer	Osimertinib
2	EGFR	S768I	Non-Small Cell Lung Cancer	Osimertinib
2	ERBB2	Amplification	Colorectal Cancer	Lapatinib + Trastuzumab
2	ERBB2	Amplification	Colorectal Cancer	Trastuzumab + Pertuzumab
2	ERBB2	Amplification	Colorectal Cancer	Trastuzumab Deruxtecan
2	ERBB2	Amplification	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Trastuzumab + Carboplatin-Taxol Regimen
2	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Ado-Trastuzumab Emtansine
2	EZH2	Oncogenic Mutations (excluding Y646S, Y646H, Y646C, Y646F, Y646N, A682G and A692V)	Follicular Lymphoma	Tazemetostat
2	IDH1	Oncogenic Mutations	Chondrosarcoma	Ivosidenib
2	JAK2	Fusions	Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2	Ruxolitinib, Fedratinib
2	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Sorafenib
2	KIT	D579del, K642E, L576P, L576del, P577del, V559A, V560D, V560G, V560del, V654A, W557G, W557R, Y553_K558del	Melanoma	Imatinib
2	KRAS	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	KRAS	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	KRAS	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	MAP2K1	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	MAP2K1	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	MAP2K1	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	MAP2K2	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	MAP2K2	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	MAP2K2	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Capmatinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Crizotinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Tepotinib
2	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Crizotinib
2	NRAS	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	NRAS	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	NRAS	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	PALB2	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Rucaparib
2	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Dasatinib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Imatinib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Regorafenib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Ripretinib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Sunitinib
2	PIK3CA	Oncogenic Mutations (excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R and H1047Y)	Breast Cancer	Alpelisib + Fulvestrant
2	RAF1	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	RAF1	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	RAF1	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	RET	Fusions	Non-Small Cell Lung Cancer	Cabozantinib
2	ROS1	Fusions	Non-Small Cell Lung Cancer	Ceritinib
2	ROS1	Fusions	Non-Small Cell Lung Cancer	Lorlatinib
3	AKT1	E17K	Breast Cancer	AZD5363
3	AKT1	E17K	Ovarian Cancer, Endometrial Cancer	AZD5363
3	ARAF	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	ARAF	Oncogenic Mutations	Histiocytosis	Sorafenib
3	ARAF	Oncogenic Mutations	Non-Small Cell Lung Cancer	Sorafenib
3	BRAF	Fusions	Melanoma	Trametinib, Cobimetinib
3	BRAF	Fusions	Ovarian Cancer	Trametinib, Cobimetinib
3	BRAF	K601	Melanoma	Trametinib
3	BRAF	L597	Melanoma	Trametinib
3	BRAF	Oncogenic Mutations (excluding V600)	Histiocytosis	Cobimetinib, Trametinib
3	BRAF	V600	Histiocytosis	Vemurafenib, Dabrafenib
3	BRCA1	Oncogenic Mutations	Breast Cancer	Olaparib
3	BRCA1	Oncogenic Mutations	Breast Cancer	Talazoparib
3	BRCA1	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Olaparib
3	BRCA2	Oncogenic Mutations	Breast Cancer	Olaparib
3	BRCA2	Oncogenic Mutations	Breast Cancer	Talazoparib
3	BRCA2	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Olaparib
3	EGFR	E709_T710delinsD	Non-Small Cell Lung Cancer	Afatinib
3	EGFR	Exon 19 in-frame deletions, Exon 19 in-frame insertions, G719, L858R, L861Q, S768I	Non-Small Cell Lung Cancer	Patritumab Deruxtecan
3	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Erlotinib
3	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Gefitinib
3	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	CLN-081
3	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Poziotinib
3	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Afatinib
3	ERBB2	Oncogenic Mutations	Breast Cancer	Neratinib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Neratinib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab + Pertuzumab + Docetaxel
3	ERCC2	Oncogenic Mutations	Bladder Cancer	Cisplatin
3	ESR1	Oncogenic Mutations	Breast Cancer	Fulvestrant
3	FGFR1	Amplification	Lung Squamous Cell Carcinoma	Debio1347, Infigratinib, Erdafitinib
3	FGFR3	G380R, K650, S371C	Bladder Cancer	Erdafitinib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Crenolanib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Quizartinib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Sorafenib
3	HRAS	Oncogenic Mutations	Bladder Urothelial Carcinoma	Tipifarnib
3	HRAS	Oncogenic Mutations	Head and Neck Squamous Cell Carcinoma	Tipifarnib
3	IDH1	R132	Glioma	Ivosidenib
3	JAK2	PCM1-JAK2 Fusion	Chronic Eosinophilic Leukemia, NOS	Ruxolitinib
3	KMT2A	Fusions	Acute Myeloid Leukemia	SNDX-5613
3	KMT2A	Fusions	B-Lymphoblastic Leukemia/Lymphoma	SNDX-5613
3	KRAS	G12C	Colorectal Cancer	Adagrasib, Adagrasib + Cetuximab
3	KRAS	G12C	Hepatobiliary Cancer, Tubular Adenoma of the Colon, Esophagogastric Cancer, Anal Cancer, Small Bowel Cancer, Gastrointestinal Neuroendocrine Tumor	Adagrasib
3	KRAS	G12C	Pancreatic Adenocarcinoma	Adagrasib
3	KRAS	G12C	Pancreatic Adenocarcinoma	Sotorasib
3	KRAS	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MAP2K1	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MAP2K1	Oncogenic Mutations	Melanoma, Non-Small Cell Lung Cancer, Low-Grade Serous Ovarian Cancer	Trametinib, Cobimetinib
3	MAP2K2	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MET	Amplification	Non-Small Cell Lung Cancer	Telisotuzumab Vedotin
3	MET	Y1003	Non-Small Cell Lung Cancer	Tepotinib, Capmatinib, Crizotinib
3	MTOR	E2014K, E2419K	Bladder Cancer	Everolimus
3	MTOR	L2209V, L2427Q	Renal Cell Carcinoma	Temsirolimus
3	MTOR	Q2223K	Renal Cell Carcinoma	Everolimus
3	NPM1	Oncogenic Mutations	Acute Myeloid Leukemia	SNDX-5613
3	NRAS	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	NRAS	Oncogenic Mutations	Melanoma	Binimetinib
3	NRAS	Oncogenic Mutations	Thyroid Cancer	Selumetinib + Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol
3	NRG1	Fusions	All Solid Tumors	Zenocutuzumab
3	NRG1	Fusions	Non-Small Cell Lung Cancer	Seribantumab
3	NTRK1	Fusions	All Solid Tumors	Repotrectinib
3	NTRK2	Fusions	All Solid Tumors	Repotrectinib
3	NTRK3	Fusions	All Solid Tumors	Repotrectinib
3	PTCH1	Truncating Mutations	Medulloblastoma	Sonidegib, Vismodegib
3	RAF1	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib
3	ROS1	Fusions	Non-Small Cell Lung Cancer	Repotrectinib
3	TP53	Y220C	All Solid Tumors	PC14586
3	TSC2	Oncogenic Mutations	Perivascular Epithelioid Cell Tumor	ABI-009
4	ARID1A	Truncating Mutations	All Solid Tumors	PLX2853
4	ARID1A	Truncating Mutations	All Solid Tumors	Tazemetostat
4	BRAF	G464, G469A, G469R, G469V	All Solid Tumors	PLX8394
4	BRAF	K601	All Solid Tumors	PLX8394
4	BRAF	L597	All Solid Tumors	PLX8394
4	CCNE1	Amplification	All Solid Tumors	RP-6306, BLU-222
4	CDK12	Truncating Mutations	All Solid Tumors	Pembrolizumab, Nivolumab, Cemiplimab
4	CDK4	Amplification	Dedifferentiated Liposarcoma, Well-Differentiated Liposarcoma	Palbociclib, Abemaciclib
4	CDKN2A	Oncogenic Mutations	All Solid Tumors	Palbociclib, Ribociclib, Abemaciclib
4	EGFR	A289V, R108K, T263P	Glioma	Lapatinib
4	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	Amplification	Glioma	Lapatinib
4	EGFR	D761Y	Non-Small Cell Lung Cancer	Osimertinib
4	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Erlotinib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Gefitinib
4	EGFR	L718V	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	L747P	Non-Small Cell Lung Cancer	Afatinib
4	FGFR1	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR2	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR3	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FLI1	EWSR1-FLI1 Fusion	Ewing Sarcoma, Ewing Sarcoma of Soft Tissue	TK216
4	KDM6A	Oncogenic Mutations	Bladder Cancer	Tazemetostat
4	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Nilotinib
4	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Pazopanib
4	KRAS	G12D	All Solid Tumors	RMC-6236
4	KRAS	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib, Binimetinib
4	MDM2	Amplification	Dedifferentiated Liposarcoma, Well-Differentiated Liposarcoma	Milademetan
4	MET	Fusions	All Solid Tumors	Crizotinib
4	MTOR	Oncogenic Mutations	All Solid Tumors	Everolimus, Temsirolimus
4	NF1	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib
4	NRAS	Oncogenic Mutations	Melanoma	Binimetinib + Ribociclib
4	PIK3CA	H1047R	All Solid Tumors (excluding Colorectal Cancer)	LOXO-783
4	PIK3CA	H1047R	Breast Cancer	LOXO-783 + Fulvestrant, LOXO-783 + Fulvestrant + Abemaciclib, LOXO-783 + LY3484356, LOXO-783 + LY3484356 + Abemaciclib, LOXO-783 + Aromatase Inhibition Therapy + Abemaciclib, LOXO-783 + Nab-paclitaxel
4	PIK3CA	Oncogenic Mutations	All Solid Tumors	RLY-2608
4	PIK3CA	Oncogenic Mutations	Breast Cancer	RLY-2608 + Fulvestrant
4	PTEN	Oncogenic Mutations	All Solid Tumors	GSK2636771, AZD8186
4	SF3B1	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	SF3B1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	SF3B1	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	SMARCB1	Oncogenic Mutations	All Liquid Tumors	Tazemetostat
4	SRSF2	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	SRSF2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	SRSF2	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	STK11	Oncogenic Mutations	Non-Small Cell Lung Cancer	Bemcentinib + Pembrolizumab
4	U2AF1	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	U2AF1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	U2AF1	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	ZRSR2	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	ZRSR2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	ZRSR2	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
R2	ALK	C1156Y	Non-Small Cell Lung Cancer	Crizotinib
R2	ALK	G1202R	Non-Small Cell Lung Cancer	Alectinib
R2	ALK	G1269A	Non-Small Cell Lung Cancer	Crizotinib
R2	ALK	I1171N	Non-Small Cell Lung Cancer	Alectinib
R2	ALK	L1196M	Non-Small Cell Lung Cancer	Crizotinib
R2	BTK	C481F	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R2	BTK	C481R	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R2	BTK	C481Y	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R2	BTK	T316A	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R2	BTK	T474I	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R2	BTK	T474S	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Ibrutinib
R2	EGFR	C797G	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	C797S	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	D761Y	Non-Small Cell Lung Cancer	Gefitinib
R2	EGFR	G724S	Non-Small Cell Lung Cancer	Osimertinib
R2	EGFR	L718V	Non-Small Cell Lung Cancer	Osimertinib
R2	KIT	A829P	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	A829P	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	C809G	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	C809G	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	D816	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	D816	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	D820	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	D820	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	N822	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	N822	Gastrointestinal Stromal Tumor	Sunitinib
R2	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	Y823D	Gastrointestinal Stromal Tumor	Imatinib
R2	KIT	Y823D	Gastrointestinal Stromal Tumor	Sunitinib
R2	MET	Amplification	Non-Small Cell Lung Cancer	Erlotinib, Gefitinib, Osimertinib
R2	MET	D1228N	Non-Small Cell Lung Cancer	Crizotinib, Cabozantinib, Capmatinib
R2	MET	Y1230H	Non-Small Cell Lung Cancer	Crizotinib, Capmatinib
R2	NTRK1	G595R	All Solid Tumors	Entrectinib
Dx1	ABL1	BCR-ABL1 Fusion	AML with BCR-ABL1	
Dx1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1	
Dx1	ABL1	BCR-ABL1 Fusion	Chronic Myeloid Leukemia, BCR-ABL1+	
Dx1	ABL1	BCR-ABL1 Fusion	Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1	
Dx1	ABL1	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx1	ABL2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx1	ALK	Fusions	ALK Positive Large B-Cell Lymphoma	
Dx1	ALK	Fusions	Anaplastic Large-Cell Lymphoma ALK Positive	
Dx1	CBFB	CBFB-MYH11 Fusion	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11	
Dx1	CEBPA	Oncogenic Mutations	AML with Biallelic Mutations of CEBPA	
Dx1	CRLF2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx1	DEK	DEK-NUP214 Fusion	AML with t(6;9)(p23;q34.1);DEK-NUP214	
Dx1	EPOR	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx1	FGFR1	Fusions	Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement	
Dx1	IL3	IGH-IL3 Fusion	B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH	
Dx1	IRF4	Fusions	Large B-Cell Lymphoma with IRF4 Rearrangement	
Dx1	JAK2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx1	JAK2	PCM1-JAK2 Fusion	Myeloid/Lymphoid Neoplasms with PCM1-JAK2	
Dx1	KMT2A	Fusions	B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3);KMT2A Rearranged	
Dx1	KMT2A	Fusions	Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged	
Dx1	KMT2A	KMT2A-MLLT3 Fusion	AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A	
Dx1	MYC	Fusions	High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements	
Dx1	NPM1	Oncogenic Mutations	AML with Mutated NPM1	
Dx1	PDGFRA	Fusions	Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement	
Dx1	PDGFRB	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx1	PDGFRB	Fusions	Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement	
Dx1	RARA	Fusions	APL with PML-RARA	
Dx1	RBM15	RBM15-MRTFA Fusion	AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1	
Dx1	RUNX1	ETV6-RUNX1 Fusion	B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1	
Dx1	RUNX1	Oncogenic Mutations	AML with Mutated RUNX1	
Dx1	RUNX1	RUNX1-RUNX1T1 Fusion	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	
Dx1	TCF3	TCF3-PBX1 Fusion	B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1	
Dx1	TYK2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx2	ASXL1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	ASXL1	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	BCL2	Fusions	High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements	
Dx2	BCL2	IGH-BCL2 Fusion	Follicular Lymphoma	
Dx2	BCL6	Fusions	High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements	
Dx2	BCOR	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	BCOR	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	BRAF	V600E	Hairy Cell Leukemia	
Dx2	BRAF	V600E	Langerhans Cell Histiocytosis	
Dx2	CALR	Oncogenic Mutations	Essential Thrombocythemia	
Dx2	CALR	Oncogenic Mutations	MDS/MPN with Ring Sideroblasts and Thrombocytosis	
Dx2	CALR	Oncogenic Mutations	Myeloproliferative Neoplasms	
Dx2	CALR	Oncogenic Mutations	Primary Myelofibrosis	
Dx2	CBL	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	CBL	Oncogenic Mutations	Juvenile Myelomonocytic Leukemia	
Dx2	CBL	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	CCND1	IGH-CCND1 Fusion	Mantle Cell Lymphoma	
Dx2	CDKN2A	Deletion	AML with BCR-ABL1	
Dx2	CDKN2A	Deletion	B-Lymphoblastic Leukemia/Lymphoma	
Dx2	CDKN2A	Deletion	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	CREBBP	KAT6A-CREBBP Fusion	Acute Myeloid Leukemia	
Dx2	CSF3R	Oncogenic Mutations	Chronic Neutrophilic Leukemia	
Dx2	DNMT3A	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	ETNK1	Oncogenic Mutations	Atypical Chronic Myeloid Leukemia, BCR-ABL1-	
Dx2	ETV6	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	EZH2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	EZH2	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	FBXW7	Oncogenic Mutations	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	FLT3	D835, D839G, I836, I867S, N676K, N841I, R834Q, Y842C	Acute Myeloid Leukemia	
Dx2	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	
Dx2	GATA1	MYB-GATA1 Fusion	Acute Myeloid Leukemia	
Dx2	GATA1	Oncogenic Mutations	Myeloid Proliferations Related to Down Syndrome	
Dx2	IDH1	Oncogenic Mutations	Acute Myeloid Leukemia	
Dx2	IDH1	R132	Myelodysplastic Syndromes	
Dx2	IDH2	Oncogenic Mutations	Acute Myeloid Leukemia	
Dx2	IKZF1	Deletion	AML with BCR-ABL1	
Dx2	IKZF1	Deletion	B-Lymphoblastic Leukemia/Lymphoma	
Dx2	IKZF1	Deletion	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Dx2	JAK2	Exon 12 in-frame deletions, Exon 12 in-frame insertions, Exon 12 missense mutations	Polycythemia Vera	
Dx2	JAK2	Oncogenic Mutations	Essential Thrombocythemia	
Dx2	JAK2	Oncogenic Mutations	Myeloproliferative Neoplasms	
Dx2	JAK2	Oncogenic Mutations	Primary Myelofibrosis	
Dx2	JAK2	V617F	MDS/MPN with Ring Sideroblasts and Thrombocytosis	
Dx2	JAK2	V617F	Polycythemia Vera	
Dx2	KIT	D816V	Systemic Mastocytosis	
Dx2	KIT	Oncogenic Mutations	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	
Dx2	KMT2A	Fusions	Acute Myeloid Leukemia	
Dx2	KMT2A	Fusions	Myeloid Sarcoma	
Dx2	KMT2A	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	KRAS	Oncogenic Mutations	Juvenile Myelomonocytic Leukemia	
Dx2	KRAS	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	LMO2	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	MPL	Oncogenic Mutations	Essential Thrombocythemia	
Dx2	MPL	Oncogenic Mutations	Myeloproliferative Neoplasms	
Dx2	MPL	Oncogenic Mutations	Primary Myelofibrosis	
Dx2	MPL	W515	MDS/MPN with Ring Sideroblasts and Thrombocytosis	
Dx2	MYC	Fusions	Burkitt Lymphoma	
Dx2	MYD88	L265P	Lymphoplasmacytic Lymphoma	
Dx2	NF1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	NF1	Oncogenic Mutations	Juvenile Myelomonocytic Leukemia	
Dx2	NOTCH1	Oncogenic Mutations	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	NPM1	Oncogenic Mutations	Myeloid Sarcoma	
Dx2	NRAS	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	NRAS	Oncogenic Mutations	Juvenile Myelomonocytic Leukemia	
Dx2	NRAS	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	PHF6	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	PHF6	Oncogenic Mutations	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	PPM1D	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	PTPN11	Oncogenic Mutations	Juvenile Myelomonocytic Leukemia	
Dx2	RUNX1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	RUNX1	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	SETBP1	D868, E858, G870, I865, S869, T864	Chronic Myelomonocytic Leukemia	
Dx2	SETBP1	D868, E858, G870, I865, S869, T864	Myelodysplastic Syndromes	
Dx2	SETBP1	Oncogenic Mutations	Atypical Chronic Myeloid Leukemia, BCR-ABL1-	
Dx2	SF3B1	Oncogenic Mutations	MDS with Ring Sideroblasts	
Dx2	SF3B1	Oncogenic Mutations	MDS/MPN with Ring Sideroblasts and Thrombocytosis	
Dx2	SF3B1	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	SRSF2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	SRSF2	P95	MDS with Ring Sideroblasts	
Dx2	SRSF2	P95	Myelodysplastic Syndromes	
Dx2	STAG2	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	TAL1	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	TCL1A	TRA-TCL1A Fusion	T-Cell Prolymphocytic Leukemia	
Dx2	TCL1B	TRA-TCL1B Fusion	T-Cell Prolymphocytic Leukemia	
Dx2	TET2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Dx2	TET2	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	TLX1	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	TLX3	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	TRA	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	TRB	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	TRD	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	TRG	Fusions	T-Lymphoblastic Leukemia/Lymphoma	
Dx2	U2AF1	Oncogenic Mutations	MDS with Ring Sideroblasts	
Dx2	U2AF1	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx2	ZRSR2	Oncogenic Mutations	MDS with Ring Sideroblasts	
Dx2	ZRSR2	Oncogenic Mutations	Myelodysplastic Syndromes	
Dx3	ASXL1	Oncogenic Mutations	AML with Myelodysplasia-Related Changes	
Dx3	BCL10	IGH-BCL10 Fusion	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)	
Dx3	BCL2	IGH-BCL2 Fusion	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	BCL6	Fusions	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	BIRC3	Oncogenic Mutations	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	
Dx3	BRAF	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	BRAF	V600E	Erdheim-Chester Disease	
Dx3	CARD11	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	CD274	Amplification	Classical Hodgkin Lymphoma	
Dx3	CD274	Amplification	Primary Mediastinal (Thymic) Large B-Cell Lymphoma	
Dx3	CD79B	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	CIITA	Fusions	Classical Hodgkin Lymphoma	
Dx3	CIITA	Fusions	Primary Mediastinal (Thymic) Large B-Cell Lymphoma	
Dx3	CREBBP	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	CREBBP	Oncogenic Mutations	Follicular Lymphoma	
Dx3	DNMT3A	Oncogenic Mutations	Angioimmunoblastic T-Cell Lymphoma	
Dx3	DNMT3A	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	ECT2L	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	EED	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	EP300	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	EP300	Oncogenic Mutations	Follicular Lymphoma	
Dx3	ETV6	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	EZH2	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	EZH2	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	EZH2	Oncogenic Mutations	Follicular Lymphoma	
Dx3	FLT3	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	FOXP1	IGH-FOXP1 Fusion	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)	
Dx3	GATA2	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	GATA3	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	ID3	Oncogenic Mutations	Burkitt Lymphoma	
Dx3	IDH1	Oncogenic Mutations	Therapy-Related Myeloid Neoplasms	
Dx3	IDH2	Oncogenic Mutations	Angioimmunoblastic T-Cell Lymphoma	
Dx3	IL7R	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	IRF4	DUSP22-IRF4 Fusion	Anaplastic Large-Cell Lymphoma ALK Negative	
Dx3	IRF4	Fusions	Primary Cutaneous DLBCL, Leg Type	
Dx3	JAK1	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	JAK3	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	KLF2	Oncogenic Mutations	Splenic Marginal Zone Lymphoma	
Dx3	KMT2D	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	KMT2D	Oncogenic Mutations	Follicular Lymphoma	
Dx3	KRAS	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	MALT1	BIRC3-MALT1 Fusion	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)	
Dx3	MALT1	IGH-MALT1 Fusion	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma)	
Dx3	MAP2K1	Oncogenic Mutations	Langerhans Cell Histiocytosis	
Dx3	MEF2B	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	MEF2B	Oncogenic Mutations	Follicular Lymphoma	
Dx3	MLLT10	PICALM-MLLT10 Fusion	T-Lymphoblastic Leukemia/Lymphoma	
Dx3	MYC	Fusions	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	MYD88	L265P	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	MYD88	L265P	Primary Cutaneous DLBCL, Leg Type	
Dx3	MYD88	L265P	Primary DLBCL of the central nervous system	
Dx3	NOTCH1	Oncogenic Mutations	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	
Dx3	NOTCH2	Oncogenic Mutations	Splenic Marginal Zone Lymphoma	
Dx3	NRAS	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	PDCD1LG2	Amplification	Classical Hodgkin Lymphoma	
Dx3	PDCD1LG2	Amplification	Primary Mediastinal (Thymic) Large B-Cell Lymphoma	
Dx3	PHF6	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	PTEN	Oncogenic Mutations	T-Lymphoblastic Leukemia/Lymphoma	
Dx3	RELN	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	RHOA	Oncogenic Mutations	Angioimmunoblastic T-Cell Lymphoma	
Dx3	RUNX1	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	SF3B1	Oncogenic Mutations	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	
Dx3	SH2B3	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	SOCS1	Oncogenic Mutations	Diffuse Large B-Cell Lymphoma, NOS	
Dx3	STAT3	Oncogenic Mutations	T-Cell Large Granular Lymphocytic Leukemia	
Dx3	STAT5B	Oncogenic Mutations	T-Cell Large Granular Lymphocytic Leukemia	
Dx3	SUZ12	Oncogenic Mutations	Early T-Cell Precursor Lymphoblastic Leukemia	
Dx3	TCF3	Oncogenic Mutations	Burkitt Lymphoma	
Dx3	TET2	Oncogenic Mutations	Angioimmunoblastic T-Cell Lymphoma	
Dx3	TNFAIP3	Oncogenic Mutations	Follicular Lymphoma	
Dx3	TNFRSF14	Oncogenic Mutations	Follicular Lymphoma	
Dx3	TP63	Fusions	Anaplastic Large-Cell Lymphoma ALK Negative	
Px1	ABL1	BCR-ABL1 Fusion	Acute Leukemias of Ambiguous Lineage	
Px1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	
Px1	ABL1	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	ABL2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	ASXL1	Oncogenic Mutations	Acute Myeloid Leukemia	
Px1	ASXL1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	
Px1	ASXL1	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	ASXL1	Oncogenic Mutations	Primary Myelofibrosis	
Px1	CALR	Oncogenic Mutations	Essential Thrombocythemia	
Px1	CALR	Oncogenic Mutations	Primary Myelofibrosis	
Px1	CBFB	CBFB-MYH11 Fusion	Acute Myeloid Leukemia	
Px1	CBL	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	CEBPA	Oncogenic Mutations	Acute Myeloid Leukemia	
Px1	CRLF2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	CSF1R	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	DEK	DEK-NUP214 Fusion	Acute Myeloid Leukemia	
Px1	EPOR	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	EZH2	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	EZH2	Oncogenic Mutations	Primary Myelofibrosis	
Px1	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	
Px1	JAK2	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	JAK2	V617F	Primary Myelofibrosis	
Px1	KIT	Oncogenic Mutations	AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1	
Px1	KMT2A	Fusions	Acute Leukemias of Ambiguous Lineage	
Px1	KMT2A	Fusions	B-Lymphoblastic Leukemia/Lymphoma	
Px1	NPM1	Oncogenic Mutations	Acute Myeloid Leukemia	
Px1	NRAS	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	PDGFRB	Fusions	B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like	
Px1	RARA	Fusions	APL with PML-RARA	
Px1	RUNX1	ETV6-RUNX1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	
Px1	RUNX1	Oncogenic Mutations	Acute Myeloid Leukemia	
Px1	RUNX1	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	RUNX1	RUNX1-RUNX1T1 Fusion	Acute Myeloid Leukemia	
Px1	SF3B1	Oncogenic Mutations	MDS/MPN with Ring Sideroblasts and Thrombocytosis	
Px1	SF3B1	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	SRSF2	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	SRSF2	Oncogenic Mutations	Primary Myelofibrosis	
Px1	TP53	Deletion	Plasma Cell Myeloma	
Px1	TP53	Oncogenic Mutations	Acute Myeloid Leukemia	
Px1	TP53	Oncogenic Mutations	AML with Myelodysplasia-Related Changes	
Px1	TP53	Oncogenic Mutations	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	
Px1	TP53	Oncogenic Mutations	Essential Thrombocythemia	
Px1	TP53	Oncogenic Mutations	Myelodysplastic Syndromes	
Px1	TP53	Oncogenic Mutations	Myeloproliferative Neoplasms	
Px1	TP53	Oncogenic Mutations	Primary Myelofibrosis	
Px1	TP53	Oncogenic Mutations	Therapy-Related Myeloid Neoplasms	
Px1	TP63	Fusions	Anaplastic Large-Cell Lymphoma ALK Negative	
Px2	ASXL1	Oncogenic Mutations	Polycythemia Vera	
Px2	CCND1	IGH-CCND1 Fusion	Plasma Cell Myeloma	
Px2	CCND3	IGH-CCND3 Fusion	Plasma Cell Myeloma	
Px2	EZH2	Oncogenic Mutations	Essential Thrombocythemia	
Px2	FGFR3	IGH-FGFR3 Fusion	Plasma Cell Myeloma	
Px2	IDH1	Oncogenic Mutations	Primary Myelofibrosis	
Px2	IDH2	Oncogenic Mutations	Essential Thrombocythemia	
Px2	IDH2	Oncogenic Mutations	Polycythemia Vera	
Px2	IDH2	Oncogenic Mutations	Primary Myelofibrosis	
Px2	MAF	IGH-MAF Fusion	Plasma Cell Myeloma	
Px2	MAFB	IGH-MAFB Fusion	Plasma Cell Myeloma	
Px2	MPL	W515K, W515L	Primary Myelofibrosis	
Px2	SF3B1	Oncogenic Mutations	Essential Thrombocythemia	
Px2	SH2B3	Oncogenic Mutations	Essential Thrombocythemia	
Px2	SRSF2	Oncogenic Mutations	Polycythemia Vera	
Px2	U2AF1	Oncogenic Mutations	Essential Thrombocythemia	
Px2	WT1	Oncogenic Mutations	Acute Myeloid Leukemia	
Px3	CXCR4	Oncogenic Mutations	Lymphoplasmacytic Lymphoma	
Px3	DUSP22	Fusions	Anaplastic Large-Cell Lymphoma ALK Negative	
Px3	FBXW7	Oncogenic Mutations	T-Lymphoblastic Leukemia/Lymphoma	
Px3	IKZF1	Deletion	B-Lymphoblastic Leukemia/Lymphoma	
Px3	MYD88	L265P	Lymphoplasmacytic Lymphoma	
Px3	NOTCH1	Oncogenic Mutations	T-Lymphoblastic Leukemia/Lymphoma	
Px3	TP53	Oncogenic Mutations	Mantle Cell Lymphoma	